Education
About Us
Working with TipRanks
Follow Us
Illumina (IT:1ILMN)
:1ILMN
1ILMN Stock Chart & Stats
Day’s Range― - ―
52-Week Range€61.00 - €145.14
Previous CloseN/A
Volume0.00
Average Volume (3M)9.00
Market Cap
$12.00B
Enterprise Value€32.32B
Total Cash (Recent Filing)$1.24B
Total Debt (Recent Filing)$2.61B
Price to Earnings (P/E)―
Beta0.51
Next Earnings
Aug 07, 2025EPS Estimate
0.89Last Dividend Ex-Date
Jun 25, 2024Dividend YieldN/A
Share Statistics
EPS (TTM)0.85
Shares Outstanding158,300,000
10 Day Avg. Volume6
30 Day Avg. Volume9
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)4.68
Price to Sales (P/S)0.00
P/FCF Ratio-416.90
Enterprise Value/Market Cap2.69
Enterprise Value/Revenue1.84
Enterprise Value/Gross Profit11.23
Enterprise Value/Ebitda-6.77
Forecast
1Y Price Target
$93.63Price Target Upside23.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering17
Illumina News
PremiumCompany Announcements
Illumina Approves Key Proposals at Annual Meeting
PremiumWeekend Updates
Tonix, Illumina, HP, Schwab & Carvana: Insider Moves!
Bulls Say, Bears Say
Bulls Say
Clinical Market ExpansionClinical penetration is expected to support revenue growth due to strong volumes from clinical customers.
Growth StrategyCEO Jacob Thaysen's refreshed strategy focusing on NovaSeq X and multiomics aims to penetrate large clinical markets, driving revenue growth.
Instrument RevenueInstrument revenue exceeded expectations, driven by better than expected NovaSeq X placements.
Bears Say
China Tariff And Ban ImpactIllumina faces significant challenges due to recent import bans of sequencers into China and tariff impacts, leading to lowered revenue expectations.
Competitive PressuresCompetition from Roche presents a meaningful risk to Illumina, impacting its market position.
Research Market DeclineConsumables revenue fell below expectations due to a decline in the research market.
Options Prices
Currently, No data available
---
Ownership Overview
2.68% Insiders
30.45%
Mutual Funds
26.32% Other Institutional Investors
18.08% Public Companies and Individual Investors
1ILMN FAQ
What was Illumina’s price range in the past 12 months?
Illumina lowest stock price was €61.00 and its highest was €145.14 in the past 12 months.
What is Illumina’s market cap?
Illumina’s market cap is $12.00B.
When is Illumina’s upcoming earnings report date?
Illumina’s upcoming earnings report date is Aug 07, 2025 which is in 54 days.
How were Illumina’s earnings last quarter?
Illumina released its earnings results on May 08, 2025. The company reported €0.851 earnings per share for the quarter, beating the consensus estimate of €0.825 by €0.026.
Is Illumina overvalued?
According to Wall Street analysts Illumina’s price is currently Undervalued.
Does Illumina pay dividends?
Illumina pays a Notavailable dividend of €2.688 which represents an annual dividend yield of N/A. See more information on Illumina dividends here
What is Illumina’s EPS estimate?
Illumina’s EPS estimate is 0.89.
How many shares outstanding does Illumina have?
Illumina has 158,300,000 shares outstanding.
What happened to Illumina’s price movement after its last earnings report?
Illumina reported an EPS of €0.851 in its last earnings report, beating expectations of €0.825. Following the earnings report the stock price went down -3.739%.
Which hedge fund is a major shareholder of Illumina?
Currently, no hedge funds are holding shares in IT:1ILMN
Illumina Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$93.63 (23.24% Upside)
$93.63 (23.24% Upside)
Blogger Sentiment
Bullish
IT:1ILMN Sentiment 88%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.42%
12-Months-Change
Fundamentals
Return on Equity
-23.82%
Trailing 12-Months
Asset Growth
-38.43%
Trailing 12-Months
Company Description
Illumina
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.
1ILMN Company Deck
1ILMN Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook with strong performance in certain areas like NovaSeq X placements and innovation pipeline advancements, but significant challenges in the Greater China region, research funding uncertainty, and tariff impacts. While growth areas show promise, the lowlights pose substantial risks.Read More>1ILMN Revenue Breakdown
91.33% Sequencing
8.67% Microarray
1ILMN Stock 12 Month Forecast
Average Price Target
€93.63
▲(23.24%Upside)